跳到正文
FDA 官方药品与生物制品信息·· 21 天前AI 评分56

FDA发布献血乙型肝炎表面抗原检测最终行业指南(2026年11月,FDA-2024-D-5942)

Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen Guidance for Industry November 2026

AI 导读

FDA发布献血乙型肝炎表面抗原检测最终行业指南,适用于全血及包括原料血浆在内的血液成分采集。指南指出HBV属21 CFR 630.3(h)(1)(ii)所列相关输血传播感染,须符合21 CFR 610.40检测、610.41献血者延期及630.40通知要求。文件编号FDA-2024-D-5942,公众可随时按21 CFR 10.115(g)(5)提交意见。

正文 · 原文

GUIDANCE DOCUMENT

Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen Guidance for Industry November 2026

Final

Docket Number:
FDA-2024-D-5942
Issued by:

Guidance Issuing Office

Center for Biologics Evaluation and Research

We, FDA, are providing you, blood establishments that collect blood and blood components, including Source Plasma, with recommendations for testing blood and blood components for hepatitis B virus (HBV) to reduce the risk of transfusion-transmitted HBV. The recommendations contained in this guidance apply to the collection of Whole Blood and blood components, including Source Plasma.

HBV is a relevant transfusion-transmitted infection (RTTI) (Title 21 of the Code of Federal Regulations (CFR) 630.3(h)(1)(ii)) and, therefore, subject to the testing requirements in 21 CFR 610.40, the donor deferral requirements in 21 CFR 610.41 and the donor notification requirements in 21 CFR 630.40.

Under 21 CFR 610.40(a)(1), an establishment that collects blood and blood components must test each donation of human blood or blood components for transfusion or for use in manufacturing a product, including donations intended as a component of, or used to manufacture, a medical device, for evidence of infection due to HBV. In addition, under 21 CFR 610.40(b), establishments must use, in accordance with the manufacturer’s instructions, one or more screening tests that FDA has licensed, approved or cleared as necessary to meet the testing requirement and to reduce adequately and appropriately the risk of transmission of RTTIs. This guidance provides recommendations for testing blood donations to reduce adequately and appropriately the risk of HBV transmission under these regulations.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2024-D-5942.

Questions?

来源:FDA 官方药品与生物制品信息 · fda.gov